Email Alert | RSS

北京大学学报（医学版） ›› 2019, Vol. 51 ›› Issue (1): 49-52. doi: 10.19723/j.issn.1671-167X.2019.01.009

• 论著 • 上一篇    下一篇

手术联合 125I粒子治疗口腔颌面部腺样囊性癌的疗效与相关预后因素分析

李聪,刘树铭,郑磊,黄明伟,石妍,吕晓鸣,张建国,张杰()   

  1. 北京大学口腔医学院·口腔医院,口腔颌面外科 国家口腔学研究中心 口腔数字化医疗技术和材料国家工程实验室 口腔数字医学北京市重点实验疾病临床医室,北京 100081
  • 收稿日期:2018-10-11 出版日期:2019-02-18 发布日期:2019-02-26
  • 通讯作者: 张杰 E-mail:zhangjie06@126.com

Study of surgery combined with 125I brachytherapy for adenoid cystic carcinoma of oral and maxillofacial region

Cong LI,Shu-ming LIU,Lei ZHENG,Ming-wei HUANG,Yan SHI,Xiao-ming LV,Jian-guo ZHANG,Jie ZHANG()   

  1. Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology, Beijing 100081, China
  • Received:2018-10-11 Online:2019-02-18 Published:2019-02-26
  • Contact: Jie ZHANG E-mail:zhangjie06@126.com

RICH HTML

   

PDF (PC)

摘要：

目的:回顾总结北京大学口腔医院应用手术联合 125I放射性粒子治疗口腔颌面部腺样囊性癌的疗效,并分析相关预后因素。方法:75例原发性口腔颌面部腺样囊性癌患者,行原发灶扩大切除或部分切除,经治疗计划系统(treatment planning system,TPS)制定放射性粒子植入计划,于术中或术后植入放射性粒子,处方剂量60~120 Gy。患者定期随访,采用Kaplan-Meier法评估肿瘤控制及生存情况,并应用Cox回归分析对其相关预后因素进行分析。结果:75例患者3年、5年局部控制率分别为90.0%、78.8%,T1~T2患者分别为92.2%、82.0%,T3~T4患者均为82.6%。无瘤生存率为3年74.9%、5年54.3%。总生存率3年、5年分别为86.0%、79.6%,其中T1~T2患者均为91.3%,T3~T4患者分别为73.9%、59.7%。3年、5年无远处转移生存率分别为84.4%、76.7%,其中T1~T2患者分别为83.4%、79.6%,T3~T4患者分别为86.0%、67.8%。通过COX单因素分析及多因素分析,年龄是影响患者局部控制的预后因素,肿瘤分期及肿瘤部位为影响患者生存率的预后因素。结论: 125I放射性粒子植入作为口腔颌面部腺样囊性癌术后辅助治疗可以获得较好的局部控制率、无瘤生存率及总生存率。高龄者易出现局部复发,肿瘤分期高及肿瘤位于鼻腔、鼻窦者生存率较低。

关键词: 癌, 腺样囊性, 口腔肿瘤, 近距离放射疗法, 碘放射性同位素, 预后

Abstract:

Objective: To retrospectively analyze the results of treatment outcome by surgery combined with 125I brachytherapy and correlative factors of adenoid cystic carcinoma (ACC). Methods: In the study, 75 patients with primary ACC of oral and maxillofacial region were treated by surgery combined with 125I seeds brachytherapy. Radical resection or subtotal resection was applied for the tumor. The brachytherapy treatment planning system was used to create implant plans with the prescribed dose of 60 Gy to 120 Gy. The 125I seeds were implanted intraoperatively or postoperatively. The regular follow-up was required. The Kaplan-Meier method was used to assess the tumor control rate and the patients’ survival rates. Meanwhile, the Cox regression analysis was used to find out the prognostic factors. Results: Local control rates at the end of 3 and 5 years were as follows: T1-T2, 92.2% and 82.0%; T3-T4, 82.6% and 82.6%; and overall, 90.0% and 78.8%. The disease-free survival rates were 74.9% and 54.3%, respectively. The overall survival rates for all the patients were 86.0% and 79.6%, respectively at the end of 3 and 5 years and were 91.3% and 91.3% for T1-T2 patients vs. 73.9% and 59.7% for T3-T4 patients. Distant metastasis-free survival rates at the end of 3 and 5 years were 84.4% and 76.7%, respectively. The distant metastasis-free survival rates at the end of 3 and 5 years were 83.4% and 79.6% with T1-T2 lesion compared with 86.0% and 67.8% with T3-T4 lesion. According to the COX univariate analysis and multivariate analysis, the risk of local recurrence would be raised by the age. Tumor stage and tumor site were the prognostic factors of the overall survival rates. Conclusion: 125I brachytherapy conducted as an adjuvant therapy postoperatively of ACC of oral and maxillofacial region can acquire satisfactory local-regional control, distant metastasis-free survival, disease-free survival and overall survival. Tumors are prone to recur on the older patients. Patients having advanced tumor stage or tumor located in the nasal cavity or sinuses will suffer lower survival rates.

Key words: Carcinoma, adenoid cystic, Mouth neoplasms, Brachytherapy, Iodine radioisotopes, Prognosis

中图分类号: 

  • R739.8

表1

75例患者基本情况"

Items Data
Gender,n (%)
Male 21 (28)
Female 54 (72)
Age/years, median (range) 48.0 (18-74)
Follow-up time/months, median (range) 46.8 (0.4-111.0)
Tumor site,n (%)
Parotid glands 24 (32.0)
Submandibular glands 13 (17.3)
Sublingual glands 7 (9.3)
Palate 11 (14.7)
Mouth floor 11 (14.7)
Cheek 2 (2.7)
Tongue 3 (4.0)
Parapharyngeal 1 (1.3)
Other 3 (4.0)
T stage,n (%)
T1 22 (29.3)
T2 19 (25.3)
T3 2 (2.7)
T4 23 (30.7)
Not reported 9 (12.0)
N stage,n (%)
N0 64 (85.3)
N1 3 (4.0)
Not reported 8 (10.7)
Surgical margins,n (%)
Positive 14 (18.7)
Clear 61(81.3)
[1] Kokemueller H, Eckardt A, Brachvogel P , et al. Adenoid cystic carcinoma of the head and neck: a 20 years experience[J]. Int J Oral Maxillofac Surg, 2004,33(1):25-31.
doi: 10.1054/ijom.2003.0448 pmid: 14690656
[2] Zhang CY, Xia RH, Han J , et al. Adenoid cystic carcinoma of the head and neck: clinicopathologic analysis of 218 cases in a Chinese population[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2013,115(3):368-375.
doi: 10.1016/j.oooo.2012.11.018 pmid: 23453028
[3] Tian Z, Li L, Wang L , et al. Salivary gland neoplasms in oral and maxillofacial regions: a 23-year retrospective study of 6 982 cases in an eastern Chinese population[J]. Int J Oral Maxillofac Surg, 2010,39(3):235-242.
doi: 10.1016/j.ijom.2009.10.016 pmid: 19951834
[4] 于世凤, 高岩 . 口腔组织学与病理学[M]. 北京: 北京大学医学出版社, 2005: 307.
[5] Maciejewski A, Szymczyk C, Wierzgon J . Outcome of surgery for adenoid cystic carcinoma of head and neck region[J]. J Craniomaxillofac Surg, 2002,30(1):59-61.
doi: 10.1054/jcms.2001.0265 pmid: 12064885
[6] Garden AS, Weber RS, Morrison WH , et al. The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation[J]. Int J Radiat Oncol Biol Phys, 1995,32(3):619-626.
doi: 10.1016/0360-3016(95)00122-F pmid: 7790247
[7] Mendenhall WM, Morris CG, Amdur RJ , et al. Radiotherapy alone or combined with surgery for adenoid cystic carcinoma of the head and neck[J]. Head Neck, 2004,26(2):154-162.
doi: 10.1002/hed.10380 pmid: 14762884
[8] Huang MW, Zheng L, Liu SM , et al. 125I brachytherapy alone for recurrent or locally advanced adenoid cystic carcinoma of the oral and maxillofacial region [J]. Strahlenther Onkol, 2013,189(6):502-507.
doi: 10.1007/s00066-013-0324-3
[9] Takagi M, Demizu Y, Hashimoto N , et al. Treatment outcomes of particle radiotherapy using protons or carbon ions as a single-modality therapy for adenoid cystic carcinoma of the head and neck[J]. Radiother Oncol, 2014,113(3):364-370.
doi: 10.1016/j.radonc.2014.11.031 pmid: 25467004
[10] Chen AM, Bucci MK, Weinberg V , et al. Adenoid cystic carcinoma of the head and neck treated by surgery with or without post-operative radiation therapy: prognostic features of recurrence[J]. Int J Radiat Oncol Biol Phys, 2006,66(1):152-159.
doi: 10.1016/j.ijrobp.2006.04.014 pmid: 16904520
[11] Al-Mamgani A, van Rooij P, Sewnaik A , et al. Adenoid cystic carcinoma of parotid gland treated with surgery and radiotherapy: long-term outcomes, QoL assessment and review of the literature[J]. Oral Oncol, 2012,48(3):278-283.
doi: 10.1016/j.oraloncology.2011.10.014 pmid: 22093375
[12] Jensen AD, Nikoghosyan AV, Poulakis M , et al. Combined intensity-modulated radiotherapy plus raster-scanned carbon ion boost for advanced adenoid cystic carcinoma of the head and neck results in superior locoregional control and overall survival[J]. Cancer, 2015,121(17):3001-3009.
doi: 10.1002/cncr.29443 pmid: 26043145
[13] Casler JD, Conley JJ . Surgical management of adenoid cystic carcinoma in the parotid gland[J]. Otolaryngol Head Neck Surg, 1992,106(4):332-338.
doi: 10.1177/019459989210600403 pmid: 1314372
[14] Iseli TA, Karnell LH, Preston TW , et al. Facial nerve sacrifice and radiotherapy in parotid adenoid cystic carcinoma[J]. Laryngoscope, 2008,118(10):1781-1786.
doi: 10.1097/MLG.0b013e31817fae29 pmid: 18758382
[15] Iseli TA, Karnell LH, Graham SM , et al. Role of radiotherapy in adenoid cystic carcinoma of the head and neck[J]. J Laryngol Otol, 2009,123(10):1137-1144.
doi: 10.1017/S0022215109990338 pmid: 19573256
[16] van Weert S, Bloemena E, van der Waal I , et al. Adenoid cystic carcinoma of the head and neck: a single-center analysis of 105 consecutive cases over a 30-year period[J]. Oral Oncol, 2013,49(8):824-829.
doi: 10.1016/j.oraloncology.2013.05.004 pmid: 23751614
[17] Zheng L, Zhang JG, Zhang J , et al. Preliminary results of 125I interstitial brachytherapy for locally recurrent parotid gland cancer in previously irradiated patients [J]. Head Neck, 2012,34(10):1445-1449.
doi: 10.1002/hed.21955
[18] Zheng L, Zhang JG, Song TL , et al. 125I seed implant brachythe-rapy for the treatment of parotid gland cancers in children and adolescents [J]. Strahlenther Onkol, 2013,189(5):401-406.
doi: 10.1007/s00066-013-0313-6 pmid: 23519359
[19] 郭华秋, 刘树铭, 张杰 , 等. 老年头颈癌患者 125I粒子植入治疗后的生存质量研究 [J]. 中华放射医学与防护杂志, 2013,33(5):501-504.
doi: 10.3760/cma.j.issn.0254-5098.2013.05.011
[20] Lloyd S, Yu JB, Wilson LD , et al. Determinants and patterns of survival in adenoid cystic carcinoma of the head and neck, including an analysis of adjuvant radiation therapy[J]. Am J Clin Oncol, 2011,34(1):76-81.
doi: 10.1097/COC.0b013e3181d26d45
[21] 农晓琳, 陈琦, 黎燕宁 , 等. 63例涎腺腺样囊性癌患者预后相关因素的Cox模型分析[J]. 口腔医学, 2011,31(1):1-4.
[1] 步召德, 冯梦宇, 季科. 早期胃癌行前哨淋巴结导航手术的实践与思考[J]. 北京大学学报（医学版）, 2026, 58(2): 239-243.
[2] 王海, 江一舟. 靶向血管治疗在乳腺癌精准治疗中的分子机制与临床应用[J]. 北京大学学报（医学版）, 2026, 58(2): 251-256.
[3] 罗必显, 刘洪铭, 谢伟勋, 龚渭华. 产甲胎蛋白胃癌的新临床特征和前沿科学问题[J]. 北京大学学报（医学版）, 2026, 58(2): 257-265.
[4] 付浩, 申潞艳, 黄冰洋, 马少华. 免疫治疗背景下食管鳞状细胞癌围手术期治疗的临床思考[J]. 北京大学学报（医学版）, 2026, 58(2): 266-271.
[5] 殷昊明, 王子杰, 舒帆, 张展奕, 梁会, 张树栋. 肾透明细胞癌FABP6基因长转录本的表达及意义[J]. 北京大学学报（医学版）, 2026, 58(2): 393-398.
[6] 李嘉临, 陈力侨, 唐家天, 吴艳, 王安强. 胃肝样腺癌转化治疗1例[J]. 北京大学学报（医学版）, 2026, 58(2): 399-404.
[7] 郭芷均, 俎明, 马超, 张贺军, 张静, 丁士刚. 同时性多发早期胃癌漏诊病灶的临床病理特征[J]. 北京大学学报（医学版）, 2026, 58(2): 410-415.
[8] 潘子晨, 陈凯, 侯钰坤, 杨博涵, 张继新, 马永蔌, 田孝东, 杨尹默. 胰腺腺鳞癌临床病理特征与分子机制研究进展[J]. 北京大学学报（医学版）, 2026, 58(2): 431-435.
[9] 张铃福, 陈明, 赵小宇, 王港, 崔龙, 凌晓锋, 王立新, 徐智, 郭丽梅, 侯纯升. 原发灶局限于胆囊壁内胆囊癌大体分型及其与预后和癌前病变的相关性[J]. 北京大学学报（医学版）, 2026, 58(1): 184-189.
[10] 高雅静, 李正芳, 马梦思, 武丽君. SII和SIRI对白塞病葡萄膜炎的风险预测及疾病活动度和预后的评估[J]. 北京大学学报（医学版）, 2025, 57(6): 1067-1073.
[11] 王晓林, 李璐瑶, 张雯, 王鸿雁. 3例子宫体中肾样腺癌的临床病理学分析[J]. 北京大学学报（医学版）, 2025, 57(6): 1208-1212.
[12] 侯卫华, 宋书杰, 石中月, 刘露, 金木兰. 食管胃结合部具有显著空泡状核特征的神经内分泌癌1例[J]. 北京大学学报（医学版）, 2025, 57(5): 1005-1009.
[13] 谢尚, 王鹿鸣, 张馨元, 冯秋实, 夏洋洋, 戴姿薇, 单小峰, 蔡志刚. 口腔鳞癌类器官库的构建及应用[J]. 北京大学学报（医学版）, 2025, 57(5): 847-851.
[14] 李浙民, 季加孚, 李国新, 李子禹, 步召德, 高翔宇, 董迪, 唐磊, 邢晓芳, 贾淑芹, 郭婷, 张连海, 陕飞, 季鑫, 王安强. 胃癌精准诊疗技术的创建与推广[J]. 北京大学学报（医学版）, 2025, 57(5): 864-867.
[15] 唐少海, 杨宝明, 李建坤, 赵丽丽, 王仪凡, 王顺祥. HDAC2介导H3K27ac修饰促进肝癌细胞的增殖和迁移[J]. 北京大学学报（医学版）, 2025, 57(5): 884-894.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
ISSN 1671-167X
CN 11-4691/R
主管单位：中华人民共和国教育部
主办单位：北京大学
地址： 北京市海淀区学院路38号 北京大学医学部 《北京大学学报（医学版）》
邮编：100191
电话：010-82801551
Email： xbbjb2@bjmu.edu.cn

《北京大学学报（医学版）》
微信公众号
版权所有 © 2018 《北京大学学报（医学版）》编辑部